This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Celia Finkelstein | |
|---|---|
| Name | Celia Finkelstein |
| Birth date | 1978 |
| Birth place | Boston, Massachusetts |
| Occupation | Scientist, educator, author |
| Alma mater | Harvard University; Massachusetts Institute of Technology; University of Cambridge |
| Known for | Molecular imaging, translational oncology, science communication |
Celia Finkelstein is an American scientist and educator known for her work in molecular imaging, translational oncology, and public science communication. She has held appointments at leading institutions and collaborated with researchers across academic, industry, and clinical sectors. Her interdisciplinary approach bridges laboratory techniques, clinical trials, and policy advocacy.
Born in Boston, Massachusetts, Finkelstein was raised in a family engaged with Massachusetts General Hospital, Harvard Medical School, and local arts organizations such as the Museum of Fine Arts, Boston. She attended Boston Latin School and matriculated at Harvard University where she completed undergraduate studies in biochemistry and took part in research at the Broad Institute. She pursued doctoral studies at the Massachusetts Institute of Technology in a joint program involving the Whitehead Institute and the Koch Institute for Integrative Cancer Research, focusing on molecular probes and imaging agents. Postdoctoral training included a fellowship at the University of Cambridge in collaboration with the Cancer Research UK Cambridge Centre and clinical investigators at Addenbrooke's Hospital.
Finkelstein began her independent career with a faculty appointment at Johns Hopkins University in the Department of Radiology and later transitioned to a joint position at Stanford University with affiliations to the Stanford Cancer Institute and the Chan Zuckerberg Biohub. Her laboratory integrated methodologies from the Human Genome Project era, leveraging CRISPR techniques originating at University of California, Berkeley and Broad Institute to develop targeted contrast agents. She has served on advisory boards for the National Institutes of Health, collaborated with the Food and Drug Administration on imaging-agent regulation, and consulted for biotech companies spun out of MIT and Harvard. Finkelstein taught courses drawing on curricula from American Association for the Advancement of Science, coordinated training with the Wellcome Trust, and mentored trainees who later took positions at the Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Mayo Clinic.
Her laboratory published in leading journals including Nature, Science, Cell, The Lancet Oncology, and Proceedings of the National Academy of Sciences. Key publications described the design of peptide-based radiotracers informed by structural studies from the Protein Data Bank, and multimodal imaging platforms combining positron emission tomography techniques developed at Brookhaven National Laboratory with optical imaging advances from California Institute of Technology. She led multicenter studies coordinated with the European Organisation for Research and Treatment of Cancer and the National Cancer Institute that evaluated imaging biomarkers for patient stratification in trials run by groups including Genentech, Roche, and AstraZeneca. Collaborators included investigators from Johns Hopkins University School of Medicine, Massachusetts General Hospital, Imperial College London, and Karolinska Institutet.
Finkelstein wrote chapters for textbooks published by Oxford University Press and Springer Nature and contributed reviews to the Annual Review of Medicine and Nature Reviews Cancer. Her methodological papers detailed protocols adapted from the Cold Spring Harbor Laboratory manual series and described analytical pipelines using platforms developed at European Molecular Biology Laboratory and the Wellcome Sanger Institute.
She received early-career recognition with awards from the Howard Hughes Medical Institute and the American Association for Cancer Research. Later honors included a named fellowship at the Radcliffe Institute for Advanced Study, a distinguished investigator award from the Society of Nuclear Medicine and Molecular Imaging, and election to the American Society for Clinical Investigation. Her translational work was recognized with industry-academic prizes from collaborations with Johnson & Johnson and a humanitarian award associated with the Bill & Melinda Gates Foundation for contributions to global diagnostics.
Finkelstein lives between Cambridge, Massachusetts and San Francisco, California and maintains active involvement with community institutions such as the Boston Symphony Orchestra and the San Francisco Museum of Modern Art. She participates in outreach programs run by the Smithsonian Institution and the Exploratorium and has served on the boards of nonprofits including the Dana Foundation and the American Cancer Society. Her family includes partners engaged in clinical practice at Brigham and Women's Hospital and academic roles at Tufts University.
Her work influenced standards for imaging-agent validation adopted by regulatory bodies including the European Medicines Agency and the Food and Drug Administration, and informed clinical trial design used by cooperative groups such as the Children's Oncology Group and the National Comprehensive Cancer Network. Trainees from her group now hold leadership positions at institutions including UCLA Health, Yale School of Medicine, and University College London. Finkelstein's contributions to translational imaging, her emphasis on reproducible protocols, and her advocacy for public engagement have been cited in policy reports by the National Academies of Sciences, Engineering, and Medicine and position papers from the World Health Organization.
Category:Living people Category:American scientists Category:Women in science